A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

Trial Details

NCT ID
NCT06533644
Phase
PHASE2
Sponsor
Syncromune, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Partial Oncolysis
  • SV-102
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Sacramento, California, United States|38.58157,-121.4944
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Male \>=18 years old.
  • Able to provide written informed consent and comply with the study procedures.
  • Participants with advanced and/or metastatic histologically or cytologically confirmed adenocarcinoma of the prostate without small cell histology …
  • Serum testosterone levels less than or equal to (\<=) 0.5 nanograms per millilitre (ng/mL) (\<=1.73 nanomoles per litre \[nmol/L\]) at screening if…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →